DOI

10.1016/S0140-6736(14)60226-9

Type

Journal

Lancet

Publication Date

29/03/2014

Volume

383

Pages

1103 - 1104

Keywords

Cost-Benefit Analysis, Humans, Immunization Programs, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, United Kingdom